FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Björn Dahlbäck

Research Profile

Chemicals & Drugs

Disorders

Protein S Deficiency

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Christina Christoffersen; Björn Dahlbäck; Ruth Frikke-Schmidt; Philip L S M Gordts; Marianne Benn; Pernille M Christensen; Anton J M Roebroek; Anne Tybjaerg-Hansen; Lars B Nielsen
The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles.
Cecilia Oslakovic; Sara Linse; Tommy Cedervall; Björn Dahlbäck
Polystyrene nanoparticles affecting blood coagulation.
Christina Lind-Halldén; Bengt Zöller; Björn Dahlbäck; Anna Dahlen; Andreas Hillarp; Christer Halldén
Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Björn Dahlbäck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christina Christoffersen; Björn Dahlbäck; Ruth Frikke-Schmidt; Philip L S M Gordts; Marianne Benn; Pernille M Christensen; Anton J M Roebroek; Anne Tybjaerg-Hansen; Lars B Nielsen
The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles.
Journal of lipid research 2012;53(10):2198-204.
2012: Cecilia Oslakovic; Sara Linse; Tommy Cedervall; Björn Dahlbäck
Polystyrene nanoparticles affecting blood coagulation.
Nanomedicine : nanotechnology, biology, and medicine 2012;8(6):981-6.
2012: Christina Lind-Halldén; Bengt Zöller; Björn Dahlbäck; Anna Dahlen; Andreas Hillarp; Christer Halldén
Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency.
Thrombosis and haemostasis 2012;108(1):94-100.
2012: Sara Elsøe; Jay W Heinecke; Andrew N Hoofnagle; Josefin Ahnström; Christoph J Binder; Harry Björkbacka; Christina Christoffersen; Björn Dahlbäck; Peter Plomgaard; Lars B Nielsen
Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL.
Atherosclerosis 2012;221(1):91-7.
2012: Sunil B Kumaraswamy; Adam Linder; Per Åkesson; Björn Dahlbäck
Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes.
Critical care (London, England) 2012;16(2):R60.
2011: Risto Cukalevski; Björn Dahlbäck; Sara Linse; Martin Lundqvist; Cecilia Oslakovic; Tommy Cedervall
Structural changes in apolipoproteins bound to nanoparticles.
Langmuir : the ACS journal of surfaces and colloids 2011;27(23):14360-9.
2011: Christina Christoffersen; Josefin Ahnström; Claudia Egerer-Sieber; Sylvain Galvani; Timothy Hla; Sunil B Kumaraswamy; Yves A Muller; Lars B Nielsen; Hideru Obinata; Madhumati Sevvana; Björn Dahlbäck
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(23):9613-8.
2011: Carl Ekman; Andreas Jönsen; Gunnar Sturfelt; Anders A Bengtsson; Björn Dahlbäck
Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.
Rheumatology (Oxford, England) 2011;50(6):1064-9.
2011: Jun Wu; Anders A Bengtsson; Carl Ekman; Anders Gottsäter; Andreas Jönsen; Bengt Lindblad; Elisabet Lindqvist; Tore Saxne; Gunnar Sturfelt; Björn Dahlbäck
Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis.
Arthritis research & therapy 2011;13(2):R62.
2010: Madhumati Sevvana; Kristin Kassler; Josefin Ahnström; Sigrid Weiler; Björn Dahlbäck; Heinrich Sticht; Yves A Muller
Mouse ApoM displays an unprecedented seven-stranded lipocalin fold: folding decoy or alternative native fold?
Journal of molecular biology 2010;404(3):363-71.
2010: Josefin Ahnström; Olof Axler; Björn Dahlbäck
HDL stimulates apoM secretion.
Protein and peptide letters 2010;17(10):1285-9.
2010: Josefin Ahnström; Pelle G Lindqvist; Ursula Walle; Björn Dahlbäck
Plasma levels of apolipoprotein M in normal and complicated pregnancy.
Acta obstetricia et gynecologica Scandinavica 2010;89(9):1214-7.
2010: Sassan Hafizi; Anna Gustafsson; Cecilia Oslakovic; Olof Idevall-Hagren; Anders Tengholm; Olivier Sperandio; Bruno O Villoutreix; Björn Dahlbäck
Tensin2 reduces intracellular phosphatidylinositol 3,4,5-trisphosphate levels at the plasma membrane.
Biochemical and biophysical research communications 2010;399(3):396-401.
2010: Carl Ekman; Anders Gottsäter; Bengt Lindblad; Björn Dahlbäck
Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia.
Clinical biochemistry 2010;43(10-11):873-6.
2010: Helena M Andersson; Márcia J Arantes; James T B Crawley; Brenda M Luken; Sinh Tran; Björn Dahlbäck; David A Lane; Suely M Rezende
Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain.
Blood 2010;115(23):4878-85.
2010: Christina Christoffersen; Tanja Xenia Pedersen; Philip L S M Gordts; Anton J M Roebroek; Björn Dahlbäck; Lars B Nielsen
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
Circulation research 2010;106(10):1624-34.
2010: Cecilia Oslakovic; Eva A Norstrøm; Björn Dahlbäck
Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans.
The Journal of clinical investigation 2010;120(5):1396-9.
2010: C Oslakovic; M Jauhiainen; Christian Ehnholm; Björn Dahlbäck
The role of phospholipid transfer protein in lipoprotein-mediated neutralization of the procoagulant effect of anionic liposomes.
Journal of thrombosis and haemostasis : JTH 2010;8(4):766-72.
2010: C Ekman; Jonas Stenhoff; Björn Dahlbäck
Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood.
Journal of thrombosis and haemostasis : JTH 2010;8(4):838-44.
2010: Josefin Ahnström; Anders Gottsäter; Bengt Lindblad; Björn Dahlbäck
Plasma concentrations of apolipoproteins A-I, B, and M in patients with critical limb ischemia.
Clinical biochemistry 2010;43(6):599-603.
2010: Josefin Ahnström; Anders Gottsäter; Bengt Lindblad; Björn Dahlbäck
Plasma concentrations of apolipoproteins A-I, B and M in patients with abdominal aortic aneurysms.
Clinical biochemistry 2010;43(4-5):407-10.
2010: Carl Ekman; Adam Linder; Per Akesson; Björn Dahlbäck
Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes.
Critical care (London, England) 2010;14(4):R158.
2010: Sinh Tran; Björn Dahlbäck
Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S.
Journal of thrombosis and haemostasis : JTH 2010;8(1):129-36.
2010: Sassan Hafizi; Emma Sernstad; Jerome D Swinny; Maria F Gomez; Björn Dahlbäck
Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects.
The international journal of biochemistry & cell biology 2010;42(1):52-61.
2010: Carl Ekman; Despina Flondell Site; Anders Gottsäter; Bengt Lindblad; Björn Dahlbäck
Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms.
Clinical biochemistry 2010;43(1-2):110-4.
2009: Madhumati Sevvana; Josefin Ahnström; Claudia Egerer-Sieber; Harald A Lange; Björn Dahlbäck; Yves A Muller
Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M.
Journal of molecular biology 2009;393(4):920-36.
2009: Michael J Krisinger; Li Jun Guo; Gian Luca Salvagno; Gian Cesare Guidi; Giuseppe Lippi; Björn Dahlbäck
Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma.
The FEBS journal 2009;276(22):6586-602.
2009: Peter Plomgaard; R P F Dullaart; R de Vries; A K Groen; Björn Dahlbäck; L B Nielsen
Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
Journal of internal medicine 2009;266(3):258-67.
2009: Anna Gustafsson; Danuta Martuszewska; Martin Johansson; Carl Ekman; Sassan Hafizi; Börje Ljungberg; Björn Dahlbäck
Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4742-9.
2009: Erik Hellstrand; Iseult Lynch; Astra Andersson; Torbjörn Drakenberg; Björn Dahlbäck; Kenneth A Dawson; Sara Linse; Tommy Cedervall
Complete high-density lipoproteins in nanoparticle corona.
The FEBS journal 2009;276(12):3372-81.
2009: Lars B Nielsen; Christina Christoffersen; Josefin Ahnström; Björn Dahlbäck
ApoM: gene regulation and effects on HDL metabolism.
Trends in endocrinology and metabolism: TEM 2009;20(2):66-71.
2009: Cecilia Oslakovic; Michael J Krisinger; Astra Andersson; Matti Jauhiainen; Christian Ehnholm; Björn Dahlbäck
Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins.
The Journal of biological chemistry 2009;284(9):5896-904.
2009: Björn Dahlbäck; L B Nielsen
Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation?
Cellular and molecular life sciences : CMLS 2009;66(4):559-64.
2009: Anna Gustafsson; Anna-Karin Boström; Börje Ljungberg; Håkan Axelson; Björn Dahlbäck
Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.
PloS one 2009;4(10):e7575.
2009: Danuta Martuszewska; Börje Ljungberg; Martin Johansson; Göran Landberg; Cecilia Oslakovic; Björn Dahlbäck; Sassan Hafizi
Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer.
PloS one 2009;4(2):e4350.
2008: Lars Bo Nielsen; Björn Dahlbäck
Lipid metabolism: why is apoM an apolipoprotein?
Current opinion in lipidology 2008;19(6):622-3.
2008: Josefin Ahnström; Olof Axler; Matti Jauhiainen; Veikko Salomaa; Aki S Havulinna; Christian Ehnholm; Ruth Frikke-Schmidt; Anne Tybjaerg-Hansen; Björn Dahlbäck
Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies.
Journal of lipid research 2008;49(9):1912-7.
2008: Kenneth Segers; Björn Dahlbäck; Jan Rosing; Gerry A F Nicolaes
Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin.
The Journal of biological chemistry 2008;283(33):22573-81.
2008: Mårten Steen; Sinh Tran; Ludovic Autin; Bruno Villoutreix; Ann-Louise Tholander; Björn Dahlbäck
Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis.
The Journal of biological chemistry 2008;283(30):20805-12.
2008: Christina Christoffersen; Josefin Ahnström; Olof Axler; Erik Ilsø Christensen; Björn Dahlbäck; Lars B Nielsen
The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma.
The Journal of biological chemistry 2008;283(27):18765-72.
2008: Björn Dahlbäck
Advances in understanding pathogenic mechanisms of thrombophilic disorders.
Blood 2008;112(1):19-27.
2008: Marc Tjwa; Lola Bellido-Martin; Yuan Lin; Esther Lutgens; Stephane Plaisance; Françoise Bono; Nathalie Delesque-Touchard; Caroline Hervé; Rute Moura; An D Billiau; Cristina Aparicio; Marcel Levi; Mat Daemen; Mieke Dewerchin; Florea Lupu; Jef Arnout; Jean-Marc Herbert; Mark Waer; Pablo García de Frutos; Björn Dahlbäck; Peter Carmeliet; Marc F Hoylaerts; Lieve Moons
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes.
Blood 2008;111(8):4096-105.
2008: Lisbeth F A Maurissen; M Christella L G D Thomassen; Gerry A F Nicolaes; Björn Dahlbäck; Guido Tans; Jan Rosing; Tilman M Hackeng
Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation.
Blood 2008;111(6):3034-41.
2008: Sinh Tran; Eva A Norstrøm; Björn Dahlbäck
Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.
The Journal of biological chemistry 2008;283(11):6648-55.
2008: Olof Axler; Josefin Ahnström; Björn Dahlbäck
Apolipoprotein M associates to lipoproteins through its retained signal peptide.
FEBS letters 2008;582(5):826-8.
2008: Christina Christoffersen; Matti Jauhiainen; Markus Moser; Bo Porse; Christian Ehnholm; Michael Boesl; Björn Dahlbäck; Lars B Nielsen
Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice.
The Journal of biological chemistry 2008;283(4):1839-47.
2008: Karl Malm; Björn Arnljots; Björn Dahlbäck
Human activated protein C variants in a rat model of arterial thrombosis.
Thrombosis journal 2008;6():16.
2008: Pelle G Lindqvist; Björn Dahlbäck
Carriership of Factor V Leiden and evolutionary selection advantage.
Current medicinal chemistry 2008;15(15):1541-4.
2008: Björn Dahlbäck
Early days of APC resistance and FV Leiden.
Hämostaseologie 2008;28(3):103-9.
2007: Kenneth Segers; Björn Dahlbäck; Paul E Bock; Guido Tans; Jan Rosing; Gerry A F Nicolaes
The role of thrombin exosites I and II in the activation of human coagulation factor V.
The Journal of biological chemistry 2007;282(47):33915-24.
2007: Leendert A Trouw; Anders A Bengtsson; Kyra A Gelderman; Björn Dahlbäck; Gunnar Sturfelt; Anna Blom
C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack.
The Journal of biological chemistry 2007;282(39):28540-8.
2007: Kenneth Segers; Björn Dahlbäck; Gerry A F Nicolaes
Coagulation factor V and thrombophilia: background and mechanisms.
Thrombosis and haemostasis 2007;98(3):530-42.
2007: Olof Axler; Josefin Ahnström; Björn Dahlbäck
An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma.
Journal of lipid research 2007;48(8):1772-80.
2007: Josefin Ahnström; Kirsten Faber; Olof Axler; Björn Dahlbäck
Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M.
Journal of lipid research 2007;48(8):1754-62.
2007: Björn Dahlbäck
The tale of protein S and C4b-binding protein, a story of affection.
Thrombosis and haemostasis 2007;98(1):90-6.
2007: Karl Malm; Björn Arnljots; Ing-Marie Persson; Björn Dahlbäck
Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats.
Thrombosis research 2007;120(4):531-9.
2006: Sassan Hafizi; Björn Dahlbäck
Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily.
The FEBS journal 2006;273(23):5231-44.
2006: Eva A Norstrøm; Sinh Tran; Mårten Steen; Björn Dahlbäck
Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va.
The Journal of biological chemistry 2006;281(42):31486-94.
2006: Roger J S Preston; Eva Ajzner; Cristina Razzari; Stalo Karageorgi; Sonia Dua; Björn Dahlbäck; David A Lane
Multifunctional specificity of the protein C/activated protein C Gla domain.
The Journal of biological chemistry 2006;281(39):28850-7.
2006: Sassan Hafizi; Björn Dahlbäck
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.
Cytokine & growth factor reviews 2006;17(4):295-304.
2006: Christina Christoffersen; Lars B Nielsen; Olof Axler; Astra Andersson; Anders H Johnsen; Björn Dahlbäck
Isolation and characterization of human apolipoprotein M-containing lipoproteins.
Journal of lipid research 2006;47(8):1833-43.
2006: Björn Dahlbäck; Lars B Nielsen
Apolipoprotein M--a novel player in high-density lipoprotein metabolism and atherosclerosis.
Current opinion in lipidology 2006;17(3):291-5.
2006: Ludovic Autin; Mårten Steen; Björn Dahlbäck; Bruno Villoutreix
Proposed structural models of the prothrombinase (FXa-FVa) complex.
Proteins 2006;63(3):440-50.
2006: Christina Christoffersen; Björn Dahlbäck; Lars B Nielsen
Apolipoprotein M: progress in understanding its regulation and metabolic functions.
Scandinavian journal of clinical and laboratory investigation 2006;66(7):631-7.
2006: Kirsten Faber; Vibeke Hvidberg; Søren K Moestrup; Björn Dahlbäck; Lars Bo Nielsen
Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M.
Molecular endocrinology (Baltimore, Md.) 2006;20(1):212-8.
2005: Anna M Johansson; Andreas Hillarp; Torbjörn Säll; Bengt Zöller; Björn Dahlbäck; Christer Halldén
Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency.
Thrombosis and haemostasis 2005;94(5):951-7.
2005: Sassan Hafizi; Anna Gustafsson; Jonas Stenhoff; Björn Dahlbäck
The Ran binding protein RanBPM interacts with Axl and Sky receptor tyrosine kinases.
The international journal of biochemistry & cell biology 2005;37(11):2344-56.
2005: Björn Dahlbäck; Bruno Villoutreix
Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(7):1311-20.
2005: Björn Dahlbäck; Bruno Villoutreix
The anticoagulant protein C pathway.
FEBS letters 2005;579(15):3310-6.
2005: Sassan Hafizi; Filiz Ibraimi; Björn Dahlbäck
C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(8):971-3.
2005: Istvan Balogh; Sassan Hafizi; Jonas Stenhoff; Karin Hansson; Björn Dahlbäck
Analysis of Gas6 in human platelets and plasma.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(6):1280-6.
2005: Björn Dahlbäck
Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.
Journal of internal medicine 2005;257(3):209-23.
2005: Björn Dahlbäck
The importance of the protein C system in the pathogenesis of venous thrombosis.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():138-9.
2005: Roger J S Preston; Ana Villegas; Yong-Hui Sun; José Hermida; Paolo Simioni; Helen Philippou; Björn Dahlbäck; David A Lane
Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation.
The FEBS journal 2005;272(1):97-108.
2004: Yong-Hui Sun; Sinh Tran; Eva A Norstrøm; Björn Dahlbäck
Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by Gla domain-mutated human-activated protein C.
The Journal of biological chemistry 2004;279(46):47528-35.
2004: E Lanke; Anna M Johansson; Andreas Hillarp; Stefan Lethagen; Bengt Zöller; Björn Dahlbäck; Christer Halldén
Co-segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1.
Journal of thrombosis and haemostasis : JTH 2004;2(11):1918-23.
2004: Jonas Stenhoff; Björn Dahlbäck; Sassan Hafizi
Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts.
Biochemical and biophysical research communications 2004;319(3):871-8.
2004: Gerry A F Nicolaes; Kristoffer W Sørensen; Ute Friedrich; Guido Tans; Jan Rosing; Ludovic Autin; Björn Dahlbäck; Bruno Villoutreix
Altered inactivation pathway of factor Va by activated protein C in the presence of heparin.
European journal of biochemistry / FEBS 2004;271(13):2724-36.
2004: Kirsten Faber; Olof Axler; Björn Dahlbäck; Lars B Nielsen
Characterization of apoM in normal and genetically modified mice.
Journal of lipid research 2004;45(7):1272-8.
2004: Lena Kask; Leendert A Trouw; Björn Dahlbäck; Anna Blom
The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells.
The Journal of biological chemistry 2004;279(23):23869-73.
2004: Kristoffer W Sørensen; Gerry A F Nicolaes; Bruno Villoutreix; Tomio Yamazaki; Guido Tans; Jan Rosing; Björn Dahlbäck
Functional properties of recombinant factor V mutated in a potential calcium-binding site.
Biochemistry 2004;43(19):5803-10.
2004: Lena Kask; Bruno Villoutreix; Mårten Steen; Bala Ramesh; Björn Dahlbäck; Anna Blom
Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H.
Protein science : a publication of the Protein Society 2004;13(5):1356-64.
2004: Mårten Steen; Eva A Norstrøm; Ann-Louise Tholander; Paula H B Bolton-Maggs; Andrew D Mumford; John H McVey; Edward G D Tuddenham; Björn Dahlbäck
Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis.
Blood 2004;103(9):3381-7.
2004: Anna Blom; Bruno Villoutreix; Björn Dahlbäck
Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?
Molecular immunology 2004;40(18):1333-46.
2004: Anna M Blom; Bruno Villoutreix; Björn Dahlbäck
Functions of human complement inhibitor C4b-binding protein in relation to its structure.
Archivum immunologiae et therapiae experimentalis 2004;52(2):83-95.
2004: Christoph Heiring; Björn Dahlbäck; Yves A Muller
Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family.
The Journal of biological chemistry 2004;279(8):6952-8.
2004: Björn Dahlbäck
Progress in the understanding of the protein C anticoagulant pathway.
International journal of hematology 2004;79(2):109-16.
2003: Anna M Blom; Bruno Villoutreix; Björn Dahlbäck
Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function.
The Journal of biological chemistry 2003;278(44):43437-42.
2003: Mårten Steen; Maria A Miteva; Bruno Villoutreix; Tomio Yamazaki; Björn Dahlbäck
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized.
Blood 2003;102(4):1316-22.
2003: Karl Malm; Björn Dahlbäck; Björn Arnljots
Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S.
Thrombosis and haemostasis 2003;90(2):227-34.
2003: Eva A Norstrøm; Mårten Steen; Sinh Tran; Björn Dahlbäck
Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va.
The Journal of biological chemistry 2003;278(27):24904-11.
2003: Björn Dahlbäck; Bruno Villoutreix
Molecular recognition in the protein C anticoagulant pathway.
Journal of thrombosis and haemostasis : JTH 2003;1(7):1525-34.
2003: Joanna H Webb; Anna Blom; Björn Dahlbäck
The binding of protein S and the protein S-C4BP complex to neutrophils is apoptosis dependent.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2003;14(4):355-9.
2003: Eva Ajzner; Istvan Balogh; Gizella Haramura; Zoltán Boda; K Kalmár; György Pfliegler; Björn Dahlbäck; László Muszbek
Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding.
Journal of thrombosis and haemostasis : JTH 2003;1(5):943-9.
2003: Pelle G Lindqvist; Björn Dahlbäck
Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.
Acta obstetricia et gynecologica Scandinavica 2003;82(5):467-70.
2003: Martin Procházka; Catharina Happach; Karel Marsál; Björn Dahlbäck; Pelle G Lindqvist
Factor V Leiden in pregnancies complicated by placental abruption.
BJOG : an international journal of obstetrics and gynaecology 2003;110(5):462-6.
2003: Karl Malm; Björn Dahlbäck; Björn Arnljots
Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury.
Plastic and reconstructive surgery 2003;111(5):1659-66.
2003: Yong-Hui Sun; Lei Shen; Björn Dahlbäck
Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding.
Blood 2003;101(6):2277-84.
2003: Björn Dahlbäck
Successful hunt for quantitative trait locus in thrombophilia.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(3):376-7.
2003: Gerry A F Nicolaes; Björn Dahlbäck
Congenital and acquired activated protein C resistance.
Seminars in vascular medicine 2003;3(1):33-46.
2003: Gerry A F Nicolaes; Björn Dahlbäck
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Hematology/oncology clinics of North America 2003;17(1):37-61, vi.
2003: Björn Dahlbäck
The discovery of activated protein C resistance.
Journal of thrombosis and haemostasis : JTH 2003;1(1):3-9.
2003: Kristina E M Persson; Björn Dahlbäck; Andreas Hillarp
Diagnosing protein S deficiency: analytical considerations.
Clinical laboratory 2003;49(3-4):103-10.
2003: Joanna H Webb; Bruno Villoutreix; Björn Dahlbäck; Anna Blom
Role of CCP2 of the C4b-binding protein beta-chain in protein S binding evaluated by mutagenesis and monoclonal antibodies.
European journal of biochemistry / FEBS 2003;270(1):93-100.
2003: Anna Blom; Lena Kask; Björn Dahlbäck
CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b.
Molecular immunology 2003;39(10):547-56.
2002: Sassan Hafizi; Filiz Alindri; Roger Karlsson; Björn Dahlbäck
Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin.
Biochemical and biophysical research communications 2002;299(5):793-800.
2002: Mårten Steen; Bruno Villoutreix; Eva A Norstrøm; Tomio Yamazaki; Björn Dahlbäck
Defining the factor Xa-binding site on factor Va by site-directed glycosylation.
The Journal of biological chemistry 2002;277(51):50022-9.
2002: Josep Serra; Miquel Sales; Andrew Chitolie; Pere Domènech; Edoardo Rossi; Montserrat Borrell; Björn Dahlbäck
Multicentre evaluation of IL Test Free PS: a fully automated assay to quantify free protein S.
Thrombosis and haemostasis 2002;88(6):975-83.
2002: Mårten Steen; Björn Dahlbäck
Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site.
The Journal of biological chemistry 2002;277(41):38424-30.
2002: Tomio Yamazaki; Gerry A F Nicolaes; Kristoffer W Sørensen; Björn Dahlbäck
Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype.
Blood 2002;100(7):2515-21.
2002: Joanna H Webb; Anna Blom; Björn Dahlbäck
Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(5):2580-6.
2002: Pelle G Lindqvist; Per Olofsson; Björn Dahlbäck
Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants.
Obstetrics and gynecology 2002;100(2):332-6.
2002: Lena Kask; Andreas Hillarp; Bala Ramesh; Björn Dahlbäck; Anna Blom
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein.
Biochemistry 2002;41(30):9349-57.
2002: Eva A Norstrøm; Elisabeth Thorelli; Björn Dahlbäck
Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Blood 2002;100(2):524-30.
2002: Pelle G Lindqvist; Marius Kublikas; Björn Dahlbäck
Individual risk assessment of thrombosis in pregnancy.
Acta obstetricia et gynecologica Scandinavica 2002;81(5):412-6.
2002: Tusar Kanti Giri; Sara Linse; Pablo García de Frutos; Tomio Yamazaki; Bruno Villoutreix; Björn Dahlbäck
Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein.
The Journal of biological chemistry 2002;277(17):15099-106.
2002: Gerry A F Nicolaes; Björn Dahlbäck
Factor V and thrombotic disease: description of a janus-faced protein.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(4):530-8.
2002: Tomio Yamazaki; Hidehiko Saito; Björn Dahlbäck
Rapid intracellular degradation of a truncated mutant protein S (Q522X).
Thrombosis and haemostasis 2002;87(1):171-2.
2001: Kristina E M Persson; Andreas Hillarp; Björn Dahlbäck
Analytical considerations for free protein S assays in protein S deficiency.
Thrombosis and haemostasis 2001;86(5):1144-7.
2001: Anna Blom; Lena Kask; Björn Dahlbäck
Structural requirements for the complement regulatory activities of C4BP.
The Journal of biological chemistry 2001;276(29):27136-44.
2001: Ute Friedrich; Anna Blom; Björn Dahlbäck; Bruno Villoutreix
Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C.
The Journal of biological chemistry 2001;276(26):24122-8.
2001: Ute Friedrich; Gerry A F Nicolaes; Bruno Villoutreix; Björn Dahlbäck
Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va.
The Journal of biological chemistry 2001;276(25):23105-8.
2001: Bruno Villoutreix; Björn Dahlbäck; Delphine Borgel; Sophie Gandrille; Y A Muller
Three-dimensional model of the SHBG-like region of anticoagulant protein S: new structure-function insights.
Proteins 2001;43(2):203-16.
2000: Tusar Kanti Giri; Pablo García de Frutos; Björn Dahlbäck
Protein S Thr103Asn mutation associated with type II deficiency reproduced in vitro and functionally characterised.
Thrombosis and haemostasis 2000;84(3):413-9.
2000: P Evenäs; Pablo García de Frutos; Gerry A F Nicolaes; Björn Dahlbäck
The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa.
Thrombosis and haemostasis 2000;84(2):271-7.
2000: Tusar Kanti Giri; Tomio Yamazaki; Núria Sala; Björn Dahlbäck; Pablo García de Frutos
Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors.
Blood 2000;96(2):523-31.
2000: Anna Blom; K Berggârd; Joanna H Webb; G Lindahl; Bruno Villoutreix; Björn Dahlbäck
Human C4b-binding protein has overlapping, but not identical, binding sites for C4b and streptococcal M proteins.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(10):5328-36.
2000: Björn Dahlbäck
Blood coagulation.
Lancet 2000;355(9215):1627-32.
2000: Henrik Ekberg; Peter J Svensson; Mecislovas Simanaitis; Björn Dahlbäck
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.
Transplantation 2000;69(8):1577-81.
2000: Lei Shen; Björn Dahlbäck; Bruno Villoutreix
Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin.
Biochemistry 2000;39(11):2853-60.
2000: P Evenäs; Björn Dahlbäck; Pablo García de Frutos
The first laminin G-type domain in the SHBG-like region of protein S contains residues essential for activation of the receptor tyrosine kinase sky.
Biological chemistry 2000;381(3):199-209.
2000: Gerry A F Nicolaes; Bruno Villoutreix; Björn Dahlbäck
Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2000;11(1):89-100.
2000: Yolanda Espinosa-Parrilla; Tomio Yamazaki; Núria Sala; Björn Dahlbäck; Pablo García de Frutos
Protein S secretion differences of missense mutants account for phenotypic heterogeneity.
Blood 2000;95(1):173-9.
1999: Tusar Kanti Giri; Pablo García de Frutos; Tomio Yamazaki; Bruno Villoutreix; Björn Dahlbäck
In vitro characterisation of two naturally occurring mutations in the thrombin-sensitive region of anticoagulant protein S.
Thrombosis and haemostasis 1999;82(6):1627-33.
1999: P Evenäs; Pablo García de Frutos; Sara Linse; Björn Dahlbäck
Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein.
European journal of biochemistry / FEBS 1999;266(3):935-42.
1999: Ning Xu; Björn Dahlbäck
A novel human apolipoprotein (apoM).
The Journal of biological chemistry 1999;274(44):31286-90.
1999: Gerry A F Nicolaes; Bruno Villoutreix; Björn Dahlbäck
Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.
Biochemistry 1999;38(41):13584-91.
1999: Bruno Villoutreix; Anna Blom; Björn Dahlbäck
Structural prediction and analysis of endothelial cell protein C/activated protein C receptor.
Protein engineering 1999;12(10):833-40.
1999: Lei Shen; Bruno Villoutreix; Björn Dahlbäck
Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity.
Thrombosis and haemostasis 1999;82(3):1078-87.
1999: Anna Blom; J Webb; Bruno Villoutreix; Björn Dahlbäck
A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function.
The Journal of biological chemistry 1999;274(27):19237-45.
1999: Lei Shen; Bruno Villoutreix; Björn Dahlbäck
Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor.
Thrombosis and haemostasis 1999;82(1):72-9.
1999: Johan Holm; Andreas Hillarp; Bengt Zöller; L Erhardt; Erik Berntorp; Björn Dahlbäck
Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome.
Thrombosis and haemostasis 1999;81(6):857-60.
1999: Bruno Villoutreix; Anna Blom; J Webb; Björn Dahlbäck
The complement regulator C4b-binding protein analyzed by molecular modeling, bioinformatics and computer-aided experimental design.
Immunopharmacology 1999;42(1-3):121-34.
1999: Björn Dahlbäck
Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms.
The Journal of laboratory and clinical medicine 1999;133(5):415-22.
1999: Karin E Knobe; A Berntsdotter; Lei Shen; J Morser; Björn Dahlbäck; Bruno Villoutreix
Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling.
Proteins 1999;35(2):218-34.
1999: E Thorelli; Randal J Kaufman; Björn Dahlbäck
Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.
Blood 1999;93(8):2552-8.
1999: Pelle G Lindqvist; Peter J Svensson; K Marsaál; L Grennert; M Luterkort; Björn Dahlbäck
Activated protein C resistance (FV:Q506) and pregnancy.
Thrombosis and haemostasis 1999;81(4):532-7.
1999: Björn Dahlbäck
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Seminars in thrombosis and hemostasis 1999;25(3):273-89.
1999: Bengt Zöller; Pablo García de Frutos; Andreas Hillarp; Björn Dahlbäck
Thrombophilia as a multigenic disease.
Haematologica 1999;84(1):59-70.
1998: Lei Shen; A M Shah; Björn Dahlbäck; G L Nelsestuen
Enhancement of human protein C function by site-directed mutagenesis of the gamma-carboxyglutamic acid domain.
The Journal of biological chemistry 1998;273(47):31086-91.
1998: Tusar Kanti Giri; Bruno Villoutreix; Anders Wallqvist; Björn Dahlbäck; Pablo García de Frutos
Topological studies of the amino terminal modules of vitamin K-dependent protein S using monoclonal antibody epitope mapping and molecular modeling.
Thrombosis and haemostasis 1998;80(5):798-804.
1998: X He; Lei Shen; Bruno Villoutreix; Björn Dahlbäck
Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function.
The Journal of biological chemistry 1998;273(42):27449-58.
1998: Anna Blom; David G Covell; Anders Wallqvist; Björn Dahlbäck; Bruno Villoutreix
The C4b-binding protein-protein S interaction is hydrophobic in nature.
Biochimica et biophysica acta 1998;1388(1):181-9.
1998: E S Sampram; Bengt Lindblad; Björn Dahlbäck
Activated protein C resistance in patients with peripheral vascular disease.
Journal of vascular surgery 1998;28(4):624-9.
1998: P Nyberg; Björn Dahlbäck; Pablo García de Frutos
The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function.
FEBS letters 1998;433(1-2):28-32.
1998: E Thorelli; Randal J Kaufman; Björn Dahlbäck
Cleavage requirements of factor V in tissue-factor induced thrombin generation.
Thrombosis and haemostasis 1998;80(1):92-8.
1998: E Thorelli; Randal J Kaufman; Björn Dahlbäck
The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
The Journal of biological chemistry 1998;273(26):16140-5.
1998: Bruno Villoutreix; Björn Dahlbäck
Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
Protein science : a publication of the Protein Society 1998;7(6):1317-25.
1998: Bruno Villoutreix; Y Härdig; Anders Wallqvist; David G Covell; Pablo García de Frutos; Björn Dahlbäck
Structural investigation of C4b-binding protein by molecular modeling: localization of putative binding sites.
Proteins 1998;31(4):391-405.
1998: Bengt Zöller; Pablo García de Frutos; Björn Dahlbäck
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
Thrombosis and haemostasis 1998;79(4):802-7.
1998: Tusar Kanti Giri; Andreas Hillarp; Y Härdig; Bengt Zöller; Björn Dahlbäck
A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen.
Thrombosis and haemostasis 1998;79(4):767-72.
1998: Yvonne Stenberg; Torbjörn Drakenberg; Björn Dahlbäck; Johan Stenflo
Characterization of recombinant epidermal growth factor (EGF)-like modules from vitamin-K-dependent protein S expressed in Spodoptera cells--the cofactor activity depends on the N-terminal EGF module in human protein S.
European journal of biochemistry / FEBS 1998;251(3):558-64.
1998: Pelle G Lindqvist; Peter J Svensson; Björn Dahlbäck; Karel Marsál
Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss--a possible evolutionary selection mechanism.
Thrombosis and haemostasis 1998;79(1):69-73.
1998: N Xu; Björn Dahlbäck; A K Ohlin; A Nilsson
Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(1):33-9.
1998: Rachel E Simmonds; HA Ireland; David A Lane; Bengt Zöller; Pablo García de Frutos; Björn Dahlbäck
Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect.
Annals of internal medicine 1998;128(1):8-14.
1997: Lei Shen; A M Shah; Björn Dahlbäck; G L Nelsestuen
Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10.
Biochemistry 1997;36(51):16025-31.
1997: Bruno Villoutreix; Pablo García de Frutos; Magnus Lövenklev; Sara Linse; Per Fernlund; Björn Dahlbäck
SHBG region of the anticoagulant cofactor protein S: secondary structure prediction, circular dichroism spectroscopy, and analysis of naturally occurring mutations.
Proteins 1997;29(4):478-91.
1997: Lei Shen; X He; Björn Dahlbäck
Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system.
Thrombosis and haemostasis 1997;78(3):1030-6.
1997: Peter J Svensson; Göran Benoni; H Fredin; Ola Björgell; P Nilsson; U Hedlund; G Nylander; D Bergqvist; Björn Dahlbäck
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Thrombosis and haemostasis 1997;78(3):993-6.
1997: Andreas Hillarp; Bengt Zöller; Peter J Svensson; Björn Dahlbäck
The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis.
Thrombosis and haemostasis 1997;78(3):990-2.
1997: E Thorelli; Randal J Kaufman; Björn Dahlbäck
Cleavage requirements for activation of factor V by factor Xa.
European journal of biochemistry / FEBS 1997;247(1):12-20.
1997: Björn Dahlbäck
Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Seminars in hematology 1997;34(3):217-34.
1997: Björn Dahlbäck
Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
Thrombosis and haemostasis 1997;78(1):483-8.
1997: Rachel E Simmonds; Bengt Zöller; HA Ireland; E Thompson; P G de Frutos; Björn Dahlbäck; David A Lane
Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes.
Blood 1997;89(12):4364-70.
1997: Björn Dahlbäck
Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 1997;49 Suppl 1():3-5.
1997: Bruno Villoutreix; O Teleman; Björn Dahlbäck
A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity.
Journal of computer-aided molecular design 1997;11(3):293-304.
1997: Peter J Svensson; Bengt Zöller; Ingrid Mattiasson; Björn Dahlbäck
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
Journal of internal medicine 1997;241(5):379-85.
1997: Y Härdig; Andreas Hillarp; Björn Dahlbäck
The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I-cofactor function.
The Biochemical journal 1997;323 ( Pt 2)():469-75.
1997: Peter J Svensson; Bengt Zöller; Björn Dahlbäck
Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Thrombosis and haemostasis 1997;77(2):332-5.
1997: Bengt Zöller; Andreas Hillarp; Björn Dahlbäck
Activated protein C resistance caused by a common factor V mutation has a single origin.
Thrombosis research 1997;85(3):237-43.
1997: Andreas Hillarp; H Wiklund; A Thern; Björn Dahlbäck
Molecular cloning of rat C4b binding protein alpha- and beta-chains: structural and functional relationships among human, bovine, rabbit, mouse, and rat proteins.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(3):1315-23.
1997: Björn Dahlbäck
Factor V and protein S as cofactors to activated protein C.
Haematologica 1997;82(1):91-5.
1997: Bengt Zöller; Andreas Hillarp; Erik Berntorp; Björn Dahlbäck
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Annual review of medicine 1997;48():45-58.
1996: A Bengtsson; Bengt Zöller; P G de Frutos; Björn Dahlbäck; Gunnar Sturfelt
Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus.
Lupus 1996;5(6):598-601.
1996: Andreas Hillarp; Bengt Zöller; Björn Dahlbäck
Activated protein C resistance as a basis for venous thrombosis.
The American journal of medicine 1996;101(5):534-40.
1996: Björn Dahlbäck; Bengt Zöller; Andreas Hillarp
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
Haemostasis 1996;26 Suppl 4():301-14.
1996: Y Härdig; Björn Dahlbäck
The amino-terminal module of the C4b-binding protein beta-chain contains the protein S-binding site.
The Journal of biological chemistry 1996;271(34):20861-7.
1996: Björn Dahlbäck
Are we ready for factor V Leiden screening?
Lancet 1996;347(9012):1346-7.
1996: Björn Dahlbäck; Andreas Hillarp; S Rosen; Bengt Zöller
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Annals of hematology 1996;72(4):166-76.
1996: J Holm; Bengt Zöller; Erik Berntorp; Leif Erhardt; Björn Dahlbäck
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
Journal of internal medicine 1996;239(3):221-6.
1996: Bengt Zöller; J Holm; P Svensson; Björn Dahlbäck
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Thrombosis and haemostasis 1996;75(2):270-4.
1996: C Aparicio; Björn Dahlbäck
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
The Biochemical journal 1996;313 ( Pt 2)():467-72.
1995: Andreas Hillarp; Björn Dahlbäck; Bengt Zöller
Activated protein C resistance: from phenotype to genotype and clinical practice.
Blood reviews 1995;9(4):201-12.
1995: Björn Dahlbäck
[A test for APC resistance prior to prescription of oral contraceptives? Discussion about screening should be based on facts].
Läkartidningen 1995;92(48):4558, 4561.
1995: Pablo García de Frutos; Y Härdig; Björn Dahlbäck
Serum amyloid P component binding to C4b-binding protein.
The Journal of biological chemistry 1995;270(45):26950-5.
1995: Sabina Janciauskiene; Pablo García de Frutos; E Carlemalm; Björn Dahlbäck; S Eriksson
Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component.
The Journal of biological chemistry 1995;270(44):26041-4.
1995: Bengt Zöller; Björn Dahlbäck
Resistance to activated protein C caused by a factor V gene mutation.
Current opinion in hematology 1995;2(5):358-64.
1995: Björn Dahlbäck
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Thrombosis and haemostasis 1995;74(1):139-48.
1995: Björn Arnljots; Björn Dahlbäck
Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(7):937-41.
1995: Y Härdig; Pablo García de Frutos; Björn Dahlbäck
Expression and characterization of a recombinant C4b-binding protein lacking the beta-chain.
The Biochemical journal 1995;308 ( Pt 3)():795-800.
1995: Bengt Zöller; Pablo García de Frutos; Björn Dahlbäck
Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease.
Blood 1995;85(12):3524-31.
1995: Bengt Zöller; A Berntsdotter; Pablo García de Frutos; Björn Dahlbäck
Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.
Blood 1995;85(12):3518-23.
1995: X He; Lei Shen; Anders Bjartell; Johan Malm; Hans Lilja; Björn Dahlbäck
The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1995;43(6):563-70.
1995: Björn Dahlbäck
Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
The Journal of laboratory and clinical medicine 1995;125(5):566-71.
1995: Björn Arnljots; Björn Dahlbäck
Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits.
The Journal of clinical investigation 1995;95(5):1987-93.
1995: Bengt Zöller; X He; Björn Dahlbäck
Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
Thrombosis and haemostasis 1995;73(5):743-5.
1995: Björn Dahlbäck
Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
Thrombosis and haemostasis 1995;73(5):739-42.
1995: Pablo García de Frutos; Björn Dahlbäck
cDNA structure of rabbit C4b-binding protein alpha-chain. Preserved sequence motive in complement regulatory protein modules which bind C4b.
Biochimica et biophysica acta 1995;1261(2):285-9.
1995: Björn Dahlbäck
Molecular genetics of venous thromboembolism.
Annals of medicine 1995;27(2):187-92.
1995: Björn Dahlbäck
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
Journal of internal medicine 1995;237(3):221-7.
1995: Björn Dahlbäck
Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V.
Haematologica 1995;80(2 Suppl):102-13.
1995: Björn Dahlbäck
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.
Blood 1995;85(3):607-14.
1995: X He; Lei Shen; Björn Dahlbäck
Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity.
European journal of biochemistry / FEBS 1995;227(1-2):433-40.
1995: X He; Lei Shen; Anders Bjartell; Björn Dahlbäck
The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by northern blotting, in situ hybridization, and immunohistochemistry.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1995;43(1):85-96.
1995: Björn Dahlbäck
The protein C anticoagulant system: inherited defects as basis for venous thrombosis.
Thrombosis research 1995;77(1):1-43.
1995: Björn Dahlbäck
Thrombophilia: the discovery of activated protein C resistance.
Advances in genetics 1995;33():135-75.
1994: Bengt Zöller; Peter J Svensson; X He; Björn Dahlbäck
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
The Journal of clinical investigation 1994;94(6):2521-4.
1994: Andreas Hillarp; A Thern; Björn Dahlbäck
Bovine C4b binding protein. Molecular cloning of the alpha- and beta-chains provides structural background for lack of complex formation with protein S.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(9):4190-9.
1994: J Holm; Bengt Zöller; Peter J Svensson; E Berntorp; Leif Erhardt; Björn Dahlbäck
Myocardial infarction associated with homozygous resistance to activated protein C.
Lancet 1994;344(8927):952-3.
1994: Johan Malm; X H He; Anders Bjartell; Lei Shen; Per-Anders Abrahamsson; Björn Dahlbäck
Vitamin K-dependent protein S in Leydig cells of human testis.
The Biochemical journal 1994;302 ( Pt 3)():845-50.
1994: Björn Dahlbäck
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.
The Journal of clinical investigation 1994;94(3):923-7.
1994: Björn Arnljots; D Bergqvist; Björn Dahlbäck
Inhibition of microarterial thrombosis by activated protein C in a rabbit model.
Thrombosis and haemostasis 1994;72(3):415-20.
1994: Pablo García de Frutos; R I Alim; Y Härdig; Bengt Zöller; Björn Dahlbäck
Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S.
Blood 1994;84(3):815-22.
1994: Lei Shen; Björn Dahlbäck
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.
The Journal of biological chemistry 1994;269(29):18735-8.
1994: Bengt Zöller; Björn Dahlbäck
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
Lancet 1994;343(8912):1536-8.
1994: X He; Björn Dahlbäck
Rabbit plasma, unlike its human counterpart, contains no complex between protein S and C4b-binding protein.
Thrombosis and haemostasis 1994;71(4):446-51.
1994: Pablo García de Frutos; Björn Dahlbäck
Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(5):2430-7.
1994: Björn Dahlbäck
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
Haemostasis 1994;24(2):139-51.
1994: Peter J Svensson; Björn Dahlbäck
Resistance to activated protein C as a basis for venous thrombosis.
The New England journal of medicine 1994;330(8):517-22.
1994: Björn Dahlbäck; B Hildebrand
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(4):1396-400.
1993: X He; Björn Dahlbäck
Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S.
European journal of biochemistry / FEBS 1993;217(3):857-65.
1993: Andreas Hillarp; F Pardo-Manuel; R R Ruiz; S Rodriguez de Cordoba; Björn Dahlbäck
The human C4b-binding protein beta-chain gene.
The Journal of biological chemistry 1993;268(20):15017-23.
1993: M Donnér; A C Kristoffersson; E Berntorp; E Scheibel; S Thorsen; Björn Dahlbäck; I M Nilsson; L Holmberg
Two new candidate mutations in type IIA von Willebrand's disease (Arg834-->Gly, Gly846-->Arg) and one polymorphism (Tyr821-->Cys) in the A2 region of the von Willebrand factor.
European journal of haematology 1993;51(1):38-44.
1993: Y Härdig; A Rezaie; Björn Dahlbäck
High affinity binding of human vitamin K-dependent protein S to a truncated recombinant beta-chain of C4b-binding protein expressed in Escherichia coli.
The Journal of biological chemistry 1993;268(5):3033-6.
1993: Björn Dahlbäck; M Carlsson; Peter J Svensson
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(3):1004-8.
1992: Björn Dahlbäck; T Wiedmer; P J Sims
Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles.
Biochemistry 1992;31(51):12769-77.
1992: M Donnér; A C Kristoffersson; Harald Lenk; E Scheibel; Björn Dahlbäck; I M Nilsson; L Holmberg
Type IIB von Willebrand's disease: gene mutations and clinical presentation in nine families from Denmark, Germany and Sweden.
British journal of haematology 1992;82(1):58-65.
1992: Johan Malm; Martin Laurell; IM Nilsson; Björn Dahlbäck
Thromboembolic disease--critical evaluation of laboratory investigation.
Thrombosis and haemostasis 1992;68(1):7-13.
1991: M Donnér; AM Andersson; A C Kristoffersson; I M Nilsson; Björn Dahlbäck; L Holmberg
An Arg545----Cys545 substitution mutation of the von Willebrand factor in type IIB von Willebrand's disease.
European journal of haematology 1991;47(5):342-5.
1991: M Andersson; A Hanson; G Englund; Björn Dahlbäck
Inhibition of complement components C3 and C4 by cadralazine and its active metabolite.
European journal of clinical pharmacology 1991;40(3):261-5.
1990: Björn Dahlbäck; B Hildebrand; Sara Linse
Novel type of very high affinity calcium-binding sites in beta-hydroxyasparagine-containing epidermal growth factor-like domains in vitamin K-dependent protein S.
The Journal of biological chemistry 1990;265(30):18481-9.
1990: Björn Dahlbäck; B Frohm; G Nelsestuen
High affinity interaction between C4b-binding protein and vitamin K-dependent protein S in the presence of calcium. Suggestion of a third component in blood regulating the interaction.
The Journal of biological chemistry 1990;265(27):16082-7.
1990: F Pardo-Manuel; J Rey-Campos; Andreas Hillarp; Björn Dahlbäck; S Rodriguez de Cordoba
Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(12):4529-32.
1990: Björn Dahlbäck; B Hildebrand; Johan Malm
Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies.
The Journal of biological chemistry 1990;265(14):8127-35.
1990: Johan Malm; E Cohen; W Dackowski; Björn Dahlbäck; R Wydro
Expression of completely gamma-carboxylated and beta-hydroxylated recombinant human vitamin-K-dependent protein S with full biological activity.
European journal of biochemistry / FEBS 1990;187(3):737-43.
1990: Andreas Hillarp; Björn Dahlbäck
Cloning of cDNA coding for the beta chain of human complement component C4b-binding protein: sequence homology with the alpha chain.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(3):1183-7.
1990: IM Nilsson; Erik Berntorp; O Zettervall; Björn Dahlbäck
Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.
Blood 1990;75(2):378-83.
1989: Andreas Hillarp; Martin Hessing; Björn Dahlbäck
Protein S binding in relation to the subunit composition of human C4b-binding protein.
FEBS letters 1989;259(1):53-6.
1988: Andreas Hillarp; Björn Dahlbäck
Novel subunit in C4b-binding protein required for protein S binding.
The Journal of biological chemistry 1988;263(25):12759-64.
1988: Björn Dahlbäck; C Hansson; M Q Islam; J Szpirer; Claude Szpirer; Ake Lundwall; G Levan
Assignment of gene for coagulation factor V to chromosome 1 in man and to chromosome 13 in rat.
Somatic cell and molecular genetics 1988;14(5):509-14.
1988: Johan Malm; R Bennhagen; L Holmberg; Björn Dahlbäck
Plasma concentrations of C4b-binding protein and vitamin K-dependent protein S in term and preterm infants: low levels of protein S-C4b-binding protein complexes.
British journal of haematology 1988;68(4):445-9.
1988: Johan Malm; Martin Laurell; Björn Dahlbäck
Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception.
British journal of haematology 1988;68(4):437-43.
1988: Björn Dahlbäck
A new model for coagulation factor V suggesting a unique mechanism of activation.
Scandinavian journal of clinical and laboratory investigation. Supplementum 1988;191():47-61.
1986: Ake Lundwall; W Dackowski; E Cohen; M Shaffer; A Mahr; Björn Dahlbäck; Johan Stenflo; R Wydro
Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(18):6716-20.